Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare haematological malignancy
derived from the precursors of plamacytoid dendritic cells, with an aggressive clinical course …

Cell therapy has been identified as an effective method to regenerate damaged tissue. Adult
stem cells, also known as somatic stem cells or resident stem cells, are a rare population of …

Background Blastic plasmacytoid dendritic-cell neoplasm (BPDCN) is an aggressive
hematologic cancer that is caused by transformed plasmacytoid dendritic cells that …

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized
by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic
malignancy with dismal outcomes for which no standard therapy exists. We found that …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for
which we developed a nationwide network to collect data from new cases diagnosed in …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare tumour, which
usually affects elderly males and presents in the skin with frequent involvement of the bone …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an uncommon hematologic
malignancy with poor outcomes. Existing data on the clinical behavior of BPDCN are limited …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and clinically challenging
hematologic malignancy with dismal outcomes. With a median age of∼ 70 years, the …

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy
with historically poor outcomes and no worldwide consensus treatment approach. Unique …